Most shorted stocks on Wall Street
Seeking Alpha News (Mon, 5-Oct 9:35 AM ET)
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September
Globe Newswire (Tue, 1-Sep 4:46 PM ET)
Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates
Globe Newswire (Thu, 6-Aug 4:05 PM ET)
Globe Newswire (Thu, 30-Jul 4:05 PM ET)
Relay Therapeutics' $275 Million Offering Bolsters Pipeline Ambitions—Key Details for Investors
Market Chameleon (Thu, 21-May 4:15 AM ET)
Relay Therapeutics' Zovegalisib Shows 60% Early Response Rate in Rare Vascular Anomaly Trial
Market Chameleon (Tue, 19-May 6:11 AM ET)
Market Chameleon (Tue, 19-May 3:05 AM ET)
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
Relay Therapeutics trades on the NASDAQ stock market under the symbol RLAY.
As of October 7, 2026, RLAY stock price declined to $17.95 with 2,951,275 million shares trading.
RLAY has a beta of 1.50, meaning it tends to be more sensitive to market movements. RLAY has a correlation of 0.09 to the broad based SPY ETF.
RLAY has a market cap of $3.93 billion. This is considered a Mid Cap stock.
Last quarter Relay Therapeutics reported $350,000 in Revenue and -$.41 earnings per share. This fell short of revenue expectation by $-678,000 and missed earnings estimates by -$.01.
In the last 3 years, RLAY traded as high as $21.27 and as low as $1.78.
The top ETF exchange traded funds that RLAY belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.
RLAY has outperformed the market in the last year with a return of +221.1%, while the SPY ETF gained +16.9%. However, in the most recent history, RLAY shares have underperformed the stock market with its stock returning -5.0% in the last 3 month period and -7.2% for the last 2 week period, while SPY has returned +3.7% and +0.5%, respectively.
RLAY support price is $18.13 and resistance is $19.35 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RLAY shares will trade within this expected range on the day.
